Finance and markets: business, quotes, gold, energy and releases.
Fuji Pharma reported net profit of ¥2.83 billion for the year ended Sept. 30, 2026, down from ¥3.00 billion a year earlier. Revenue and operating profit rose, while earnings per share declined, according to results prepared under Japanese accounting standards.
Revenue increased to ¥62.39 billion from ¥51.68 billion in the previous year. Operating profit climbed to ¥6.36 billion from ¥4.99 billion, and pretax profit reached ¥6.18 billion, up from ¥4.46 billion.
Earnings per share were ¥111.18, compared with ¥122.94 for the year ended Sept. 30, 2025. Fuji Pharma Co. Ltd. trades under ticker 4554.TO.
When reusing this material a link to Money Talk is required.
Comments (0)
No comments yet. Be the first!